Dynavax Technologies Corporation (OQ:DVAX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2929 7th St Ste 100
BERKELEY CA 94710-2753
Tel: N/A
Website: www.dynavax.com
IR: See website
<
Key People
Arnold L. Oronsky
Independent Chairman of the Board
David F. Novack
President, Chief Operating Officer
Ryan Spencer
Chief Executive Officer, Director
Michael S. Ostrach
Chief Financial Officer, Senior Vice President, Chief Business Officer
Robert Janssen
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
 
Business Overview
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
Financial Overview
For the fiscal year ended 31 December 2019, Dynavax Technologies Corporation revenues increased from $8.2M to $35.2M. Net loss applicable to common stockholders decreased 2% to $155.9M. Revenues reflect Product revenues, net increase from $6.8M to $34.6M. Lower net loss reflects Compensation and related personnel costs decrease of 28% to $21.9M (expense), Research and development - Balancing val decrease of 7% to $32.3M (expense).
Employees: 231 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $334.38M as of Dec 31, 2019
Annual revenue (TTM): $35.22M as of Dec 31, 2019
EBITDA (TTM): -$105.16M as of Dec 31, 2019
Net annual income (TTM): -$155.87M as of Dec 31, 2019
Free cash flow (TTM): -$150.65M as of Dec 31, 2019
Net Debt Last Fiscal Year: $27.55M as of Dec 31, 2019
Shares outstanding: 86,188,763 as of Mar 6, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization